PBM
SNDX icon

Propel Bio Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Propel Bio Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-183,259
Closed -$2.25M – 20
2025
Q1 		$2.25M Hold
183,259
– – 2.62% 11
2024
Q4 		$2.42M Buy
183,259
+50,000
+38% +$856K 2.41% 11
2024
Q3 		$2.57M Buy
133,259
+50,000
+60% +$1.03M 1.49% 13
2024
Q2 		$1.71M Hold
83,259
– – 1.11% 17
2024
Q1 		$1.98M Buy
+83,259
New +$1.86M 1.15% 17

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Propel Bio Management's SNDX Position: Q2 2025 in Review

Propel Bio Management sold out of Syndax Pharmaceuticals (SNDX) in Q2 2025, closing a stake of 183,259 shares — an estimated $2.25M sold.

Propel Bio Management first reported a position in SNDX in Q1 2024 and held it in 5 quarters. The position peaked at $2.57M in Q3 2024. 216 funds tracked by Wall St. Rank hold SNDX as of Q2 2025.

  • Propel Bio Management reported no remaining Syndax Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Propel Bio Management sold 183,259 Syndax Pharmaceuticals shares in Q2 2025, an estimated $2.25M.
  • Propel Bio Management first reported a position in Syndax Pharmaceuticals in Q1 2024 and held it in 5 quarters.
  • Propel Bio Management's Syndax Pharmaceuticals position peaked at $2.57M in Q3 2024.
  • 216 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2025.

Based on Propel Bio Management's 13F filing for Q2 2025, filed 13 Aug 2025.